Wegovy for fat loss: what the evidence actually shows

How Wegovy actually reduces body fat

Fat loss happens when the body draws on stored energy because its intake has fallen below what it burns. Wegovy makes that shift easier to sustain. Semaglutide works by activating GLP-1 receptors, the same receptors stimulated by a hormone your gut releases when you eat. The result is a meaningful reduction in appetite and a slower rate of gastric emptying, so meals feel more filling for longer.

Over weeks of treatment, most people find they eat significantly less without fighting constant hunger. That sustained calorie reduction is what drives fat loss. The NHS medicines page for semaglutide explains the mechanism clearly if you want a detailed clinical summary. It is worth noting that Wegovy is designed to work alongside a reduced-calorie diet and increased physical activity, the injection supports those changes rather than replacing them.

There is also some evidence that GLP-1 receptor agonists preferentially reduce visceral fat (the fat stored around internal organs), which carries the greatest metabolic risk. If that is a particular concern for you, the page on Wegovy and belly fat covers what the data suggest about abdominal fat loss specifically.

What the trial results mean for real people

The STEP 1 trial enrolled around 1,900 adults with obesity or overweight plus at least one weight-related condition, without type 2 diabetes. After 68 weeks, those on semaglutide 2.4 mg lost an average of around 15% of their starting body weight compared with around 2.4% on placebo. Those are averages: some participants lost considerably more, some less. Results varied with adherence, diet, activity levels and individual biology.

The figure is clinically significant, a 15% reduction is enough to improve blood pressure, cholesterol, joint load and blood sugar control in many people. NICE, in its appraisal of semaglutide for weight management (TA875), concluded the evidence was sufficient to recommend it for eligible patients within specialist weight management services.

If you are comparing Wegovy with tirzepatide (Mounjaro), head-to-head data from the SURMOUNT-5 trial showed tirzepatide produced greater average weight loss, though for many people the practical difference in day-to-day life may be less important than tolerability and how the treatment fits their routine. Our page on semaglutide and fat loss sets out the full evidence picture for the ingredient across both branded products.

Who the licence covers, and where the grey areas are

Wegovy's UK licence covers adults with a BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related health condition. Those conditions include type 2 diabetes, prediabetes, raised blood pressure, dyslipidaemia and obstructive sleep apnoea, among others. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance, your prescriber can confirm whether this affects your assessment.

Having a BMI that sits within those ranges does not automatically mean Wegovy will be approved. Prescribers take the whole picture into account: your health history, any medicines you already take, conditions that might affect safety, and whether you are pregnant, planning to conceive or breastfeeding (in which case Wegovy is not recommended). People under 18 are also outside the licensed indication.

For a broader look at how the treatment landscape works, the Wegovy weight loss overview covers eligibility, access routes and what to expect from the full treatment journey. Or if cost is on your mind alongside clinical fit, our weight loss treatments page lays out what private treatment through nume includes.

Side effects and what to do about them

Gastrointestinal effects are the most commonly reported: nausea, loose stools, constipation, indigestion and burping. For the majority of people these are at their most noticeable in the first few weeks and ease once the body adjusts. Eating smaller portions, keeping well hydrated and avoiding very fatty meals can help, practical advice your prescriber will go over with you.

A smaller number of people experience fatigue, headache or dizziness, particularly around dose increases. More serious but much rarer effects include acute pancreatitis: the symptom to act on is severe stomach pain that radiates to the back, especially if it persists. Seek urgent medical help if that happens. You can also report any suspected side effect directly to the MHRA via the Yellow Card scheme.

If you are already familiar with semaglutide's profile and are thinking about whether the injection or the newer oral option suits you better, the page on Wegovy as a fat jab covers the injection route in more detail. And for those who came across 'fat jab' as a search term, the fat jab semaglutide page explains how that colloquial label relates to the licensed medicine.

Ready to explore whether Wegovy is clinically suitable for you? Speak to our prescribers, consultations are free, reviewed the same day by a GPhC-registered Independent Prescriber, and there is no obligation to proceed.